Urogen's Chief Medical Officer Insider Trade: 400K Sale Insights
A high-profile insider sale at UroGen Pharma raises questions about market signals and biotech risk. This article unp...
Fund reallocation matters when priorities shift. This intro explains why adjusting allocations supports your financial plan.
21,833 articlesA high-profile insider sale at UroGen Pharma raises questions about market signals and biotech risk. This article unp...
Unlock how to apply advanced stock market investment strategies with real world examples. From backtesting to hedging...
JPMorgan Chase's CEO says the public frustration with wealth concentration is real, and calls for policy and corporat...
AMD is positioning itself as a robust player across consumer, data center, and AI markets. This article breaks down w...
As UnitedHealth readies its 2026 earnings, investors want clarity on growth, margins, and risk. This guide breaks dow...
A seasoned executive faces a high-stakes choice: take a startup role or ride out the final years with a steady path. ...
Oracle's shares have fallen steeply as AI hype cooled. This article breaks down whether the stock is a value opportun...
Redwire stock popped tuesday as the company announced ambitious factory expansions and a second facility for space pa...
NVIDIA stock has surprised some by not rallying in 2026 despite booming AI demand. This article breaks down why the s...
Amazon ends Walmart’s long hold on the Fortune 500 top spot, posting 2025 revenue of $716.9 billion to Walmart’s $713...
A seismic shift is unfolding in housing finance: the rental market entered infrastructure era, pushing lenders to red...
Mega-cap tech values are under pressure, and the question on many minds is whether Alphabet, Apple, Microsoft kicked ...